Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy

University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom.
The Journal of allergy and clinical immunology (Impact Factor: 11.25). 03/2011; 127(3):684-5. DOI: 10.1016/j.jaci.2010.12.012
Source: PubMed
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In most of the cases the standard diagnosis of an allergic disease is based on a detailed clinical history and demonstration of sensitisation (either by skin test or in vitro testing) to a relevant allergen concordant with the history. The allergen provocation test is rarely required. However, the history of allergy diagnosis started with the patch test (1894), which is essentially a provocation test. Systematically applied allergen challenges followed, with the introduction of conjunctival (1907), nasal (1914) and bronchial provocation (1925). Besides being a diagnostic tool the allergen provocation is a long-standing model for studying the mechanisms of allergic diseases or the efficacy of antiallergic drugs. Due to safety issues and lack of standardisation in conjunction with increased availability of high quality reagents for skin tests or in vitro diagnosis the allergen challenge was almost abandoned from daily practice and reserved for research purposes.This article is protected by copyright. All rights reserved.
    Allergy 01/2015; DOI:10.1111/all.12586 · 6.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Food allergy affects 4–8 % of children, and it appears to be increasingly common. The prevalence of peanut allergy has increased in the US and internationally. Pediatricians are on the front lines of providing patient care, so disseminating guidelines and current information regarding appropriate evaluation and principles of management to them is critically important. The approach to the patient with suspected food allergy requires a detailed medical history. In vitro testing is widely available but should be ordered judiciously. Using the history to guide testing can help avoid potential pitfalls of food allergy testing, which is characterized by high false-positive rates. Component-resolved diagnostics represent a new and emerging area. Currently, this modality is most useful for peanut allergy, though further study regarding interpretation of these tests is needed. Management involves complete dietary restriction in most cases, but because accidental reactions do occur, education and emergency preparedness to treat reactions are also essential.
    06/2014; 2(2):113-118. DOI:10.1007/s40124-014-0046-8
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Most children with detectable peanut-specific IgE (P-sIgE) are not allergic to peanut. We addressed 2 non-mutually exclusive hypotheses for the discrepancy between allergy and sensitization: (1) differences in P-sIgE levels between children with peanut allergy (PA) and peanut-sensitized but tolerant (PS) children and (2) the presence of an IgE inhibitor, such as peanut-specific IgG4 (P-sIgG4), in PS patients. Two hundred twenty-eight children (108 patients with PA, 77 PS patients, and 43 nonsensitized nonallergic subjects) were studied. Levels of specific IgE and IgG4 to peanut and its components were determined. IgE-stripped basophils or a mast cell line were used in passive sensitization activation and inhibition assays. Plasma of PS subjects and patients submitted to peanut oral immunotherapy (POIT) were depleted of IgG4 and retested in inhibition assays. Basophils and mast cells sensitized with plasma from patients with PA but not PS patients showed dose-dependent activation in response to peanut. Levels of sIgE to peanut and its components could only partially explain differences in clinical reactivity between patients with PA and PS patients. P-sIgG4 levels (P = .023) and P-sIgG4/P-sIgE (P < .001), Ara h 1-sIgG4/Ara h 1-sIgE (P = .050), Ara h 2-sIgG4/Ara h 2-sIgE (P = .004), and Ara h 3-sIgG4/Ara h 3-sIgE (P = .016) ratios were greater in PS children compared with those in children with PA. Peanut-induced activation was inhibited in the presence of plasma from PS children with detectable P-sIgG4 levels and POIT but not from nonsensitized nonallergic children. Depletion of IgG4 from plasma of children with PS (and POIT) sensitized to Ara h 1 to Ara h 3 partially restored peanut-induced mast cell activation (P = .007). Differences in sIgE levels and allergen specificity could not justify the clinical phenotype in all children with PA and PS children. Blocking IgG4 antibodies provide an additional explanation for the absence of clinical reactivity in PS patients sensitized to major peanut allergens. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
    Journal of Allergy and Clinical Immunology 02/2015; 125. DOI:10.1016/j.jaci.2015.01.012 · 11.25 Impact Factor